ATE424416T1 - Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung - Google Patents

Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung

Info

Publication number
ATE424416T1
ATE424416T1 AT03725585T AT03725585T ATE424416T1 AT E424416 T1 ATE424416 T1 AT E424416T1 AT 03725585 T AT03725585 T AT 03725585T AT 03725585 T AT03725585 T AT 03725585T AT E424416 T1 ATE424416 T1 AT E424416T1
Authority
AT
Austria
Prior art keywords
tissue
hmgb1
recovery
hmgbl
treat
Prior art date
Application number
AT03725585T
Other languages
English (en)
Inventor
Marco Emilio Bianchi
Roberta Palumbo
Capogrossi Maurizio Colognesi
Federica Limana
Antonia Germani
Original Assignee
San Raffaele Centro Fond
Idi Irccs
Ct Cardiologico Monzino S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond, Idi Irccs, Ct Cardiologico Monzino S P A filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of ATE424416T1 publication Critical patent/ATE424416T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
AT03725585T 2002-07-03 2003-04-29 Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung ATE424416T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39399402P 2002-07-03 2002-07-03

Publications (1)

Publication Number Publication Date
ATE424416T1 true ATE424416T1 (de) 2009-03-15

Family

ID=30115667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725585T ATE424416T1 (de) 2002-07-03 2003-04-29 Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung

Country Status (14)

Country Link
US (1) US20060035851A1 (de)
EP (1) EP1519957B1 (de)
JP (1) JP2005537253A (de)
KR (1) KR20050054907A (de)
CN (1) CN1671742A (de)
AT (1) ATE424416T1 (de)
AU (1) AU2003228099A1 (de)
CA (1) CA2491321A1 (de)
DE (1) DE60326453D1 (de)
IL (1) IL166022A0 (de)
MX (1) MXPA05000302A (de)
NO (1) NO20050537L (de)
RU (1) RU2005102593A (de)
WO (1) WO2004004763A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4792392B2 (ja) 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
JP2008507505A (ja) * 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
AU2005333602B2 (en) 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
WO2006130697A1 (en) 2005-06-01 2006-12-07 Cytokine Pharmasciences, Inc. Hmgb1 expression and protective role of semapimod in nec
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
AU2014200688C1 (en) * 2006-10-30 2016-04-21 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
HUE035043T2 (en) * 2006-10-30 2018-05-02 Genomix Co Ltd A pharmaceutical composition for promoting functional regeneration of damaged tissue
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
RU2519714C2 (ru) 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
CN102083962B (zh) 2008-04-30 2013-03-27 吉诺米克斯股份有限公司 生物体内功能性细胞的高效采集方法
CN102076351A (zh) * 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物
EP2494977B1 (de) * 2009-10-28 2018-06-13 Genomix Co., Ltd. Geweberegenerationsförderer mit rekrutierung mesenchymaler knochenmarkstammzellen und/oder pluripotenter stammzellen in blut
ES2486321T3 (es) * 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
CN103200937B (zh) * 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
WO2014016417A1 (en) * 2012-07-26 2014-01-30 Ospedale San Raffaele Srl Hmgb1 variants and uses thereof
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
CN103316378B (zh) * 2013-06-27 2014-07-16 重庆大学 一种hmgb 1修饰的骨组织工程支架材料及其制备方法
KR102365492B1 (ko) 2015-04-22 2022-02-18 삼성전자주식회사 웨어러블 기기
CA3007877A1 (en) 2015-12-11 2017-06-15 Ruprecht-Karls-Universitat Heidelberg Combined preparations of pkm2 modulators and hmgb1
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN106244589A (zh) * 2016-08-01 2016-12-21 中国人民解放军第四军医大学 靶向hmgb1基因的rna干扰片段及其应用
AU2018213671B2 (en) * 2017-01-27 2024-06-06 Osaka University Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3617222A4 (de) 2017-04-25 2021-01-20 Shionogi & Co., Ltd Peptide zur induktion der regenerierung von gewebe und verwendung davon
EP3718561A4 (de) 2017-12-01 2021-07-21 Stemrim Inc. Therapeutikum für entzündliche darmerkrankung
CN111381050B (zh) * 2020-04-21 2023-06-20 南通大学 Reg3β/ HMGB1环路调控EAM小鼠巨噬细胞再编程的实验方法
WO2023037562A1 (ja) * 2021-09-07 2023-03-16 国立大学法人大阪大学 肺炎の治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2002255805B2 (en) * 2001-03-15 2005-03-24 North Shore Long Island Jewish Research Institute Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
KR20040018370A (ko) * 2001-05-15 2004-03-03 노쓰 쇼어-롱 아일랜드 제위시 리서치 인스티튜트 Ｈｍｇ 단편의 항염증제로서의 용도

Also Published As

Publication number Publication date
KR20050054907A (ko) 2005-06-10
EP1519957A2 (de) 2005-04-06
AU2003228099A1 (en) 2004-01-23
US20060035851A1 (en) 2006-02-16
CA2491321A1 (en) 2004-01-15
MXPA05000302A (es) 2005-08-19
JP2005537253A (ja) 2005-12-08
IL166022A0 (en) 2006-01-15
WO2004004763A3 (en) 2004-02-26
RU2005102593A (ru) 2005-10-10
EP1519957B1 (de) 2009-03-04
NO20050537L (no) 2005-02-01
DE60326453D1 (de) 2009-04-16
CN1671742A (zh) 2005-09-21
WO2004004763A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
ATE424416T1 (de) Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
NL300808I2 (nl) susoctocog alfa
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60336821D1 (de) Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
TW200501976A (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
ATE254461T1 (de) Behandlung von augenschmerzen
DE602004003587D1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DE602005019728D1 (de) Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
TW200505473A (en) Compositions and methods for treatment of psoriasis
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
ATE399011T1 (de) Substituierte diketopiperazine als oxytocin- antagonisten
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
DK1579859T3 (da) Anvendelse af N-(2-arylpropionyl)-sulfonamider til behandling af rygmarvsskader
DE60232154D1 (de) Prophylaktische und therapeutische verwendung von hydroxysteroiden
EA200401395A1 (ru) Способ лечения или профилактики микробных заболеваний ногтя субъекта (варианты), композиция для местного нанесения на ноготь и способ ее получения
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
EA200401448A1 (ru) Способ защиты эндотелиальных и эпителиальных клеток во время химиотерапии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties